Endogenous Cushing’s Syndrome (CS) – Market Access and Reimbursement Insights Report – 2025

Endogenous Cushing’s Syndrome (CS) Market Access and Reimbursement Insights

Thelansis’s “Endogenous Cushing’s Syndrome (CS) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Endogenous Cushing’s Syndrome (CS) Overview

Endogenous Cushing’s syndrome (CS) is an uncommon endocrine disorder characterized by an overproduction of cortisol stemming from either ACTH-dependent conditions, typically an ACTH-producing pituitary adenoma (known as Cushing’s disease), or ACTH-independent causes, most commonly a benign adrenal adenoma. While the primary effects of endogenous Cushing’s syndrome are evident in its phenotypic changes and metabolic consequences, it also significantly impacts other endocrine axes. Inappropriate cortisol secretion can disrupt the activity of the hypothalamus-pituitary-thyroid axis, resulting in clinical and biochemical features indicative of “central hypothyroidism.” Medical treatment for Cushing’s disease is primarily utilized as a secondary option following unsuccessful surgery or recurrence. It involves various pituitary-directed medications, adrenal steroidogenesis inhibitors, and a glucocorticoid receptor blocker, some of which have received approval from the US Food and Drug Administration (FDA). Notably, recent consensus guidelines from the Pituitary Society endorse osilodrostat, an oral 11β-hydroxylase inhibitor, as an effective FDA-approved medical therapy for Cushing’s disease. Despite achieving remission, patients often contend with several persistent comorbidities that can significantly impact their quality of life. Hence, prompt and accurate diagnosis, followed by timely intervention, is imperative for mitigating the chronic complications associated with excessive glucocorticoid levels and enhancing patient well-being.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Endogenous Cushing’s Syndrome (CS) – Market Access and Reimbursement Insights Report – 2025